Evidence map›Paper›PMID 42724564›Full record

ArticleAmerican journal of cancer research2026

Transcriptional activation of ALOX5 by c-Myc drives malignant progression and M2 macrophage polarization in clear cell renal cell carcinoma.

Changjie Ren, Yijun Tian, Xinran Zhang, Denglong Wu, Weidong Zhou, Xue Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Changjie RenShanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Sino-French Cooperative Central Lab, Shanghai Pudong Gongli Hospital Shanghai 200135, China.
Yijun TianShanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Sino-French Cooperative Central Lab, Shanghai Pudong Gongli Hospital Shanghai 200135, China.
Xinran ZhangShanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Sino-French Cooperative Central Lab, Shanghai Pudong Gongli Hospital Shanghai 200135, China.
Denglong WuDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University Shanghai 200065, China.
Weidong ZhouDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University Shanghai 200065, China.
Xue ZhangShanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Sino-French Cooperative Central Lab, Shanghai Pudong Gongli Hospital Shanghai 200135, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is an aggressive malignancy with poor prognosis, but the molecular mechanisms linking oncogenic signaling to macrophage polarization remain unclear. In this study, we identify arachidonate 5-lipoxygenase (ALOX5) as an oncogenic factor in ccRCC. Multi-omics analyses and clinical validation show that ALOX5 is up-regulated in ccRCC tissues and its high expression is associated with advanced tumor stage and poor survival. Functional assessments reveal that silencing ALOX5 in ccRCC cells inhibits cell proliferation, migration, invasion, and epithelial-to-mesenchymal transition (EMT)

Indexed as

ALOX5ccRCCc-MycTAMsTIME

Identifiers

PMID42724564
PMCPMC13559356

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.